EPA:ERYP • FR0011471135
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ERYTECH PHARMA (ERYP.PA).
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.718M -29.62% | 4.18M 12.43% | 6.648M 59.04% | 21.067M 216.89% | 24.704M 17.26% | 1.53M -93.81% | 1.683M 10.00% | |
| EBITDA YoY % growth | -63.841M -6.65% | -51.138M 19.90% | -22.528M 55.95% | -27.54M -22.25% | 6.12M 122.22% | N/A | N/A | |
| EBIT YoY % growth | -68.832M -7.43% | -56.515M 17.89% | -27.147M 51.96% | -27.8M -2.41% | -11.863M 57.33% | -33.129M -179.26% | -33.712M -1.76% | |
| Operating Margin | -1,851.32% | -1,352.03% | -408.35% | -131.96% | -48.02% | -2,165.27% | -2,003.11% | |
| EPS YoY % growth | N/A -5.11% | N/A 17.43% | N/A 51.41% | -1.05 22.35% | -0.55 47.80% | N/A | N/A |
All data in EUR
| Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 57.45% | -0.21 -94.73% | -0.22 38.89% | -0.26 -38.89% |
| Revenue Q2Q % growth | 299.88K -44.36% | 320.28K -66.43% | 333.54K -28.88% | 380.46K -93.32% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.314M 49.55% | -6.734M 72.24% | -7.016M -26.02% | -7.997M -176.80% |
All data in EUR
9 analysts have analysed ERYP.PA and the average price target is 3.67 EUR. This implies a price increase of 358.43% is expected in the next year compared to the current price of 0.801.
The consensus EPS estimate for the next earnings of ERYTECH PHARMA (ERYP.PA) is -0.2 EUR and the consensus revenue estimate is 299.88K EUR.
The consensus rating for ERYTECH PHARMA (ERYP.PA) is 42.2222 / 100 . This indicates that analysts generally have a neutral outlook on the stock.